The Defense Threat Reduction Agency, a branch of the U.S. Department of Defense, has awarded the Israeli diagnostics company MeMed a $9.2 million contract to fund completion of MeMed’s point-of-care (POC) platform for distinguishing bacterial from viral infections. MeMed hopes this test will help combat over-prescription of antibiotics by reducing diagnostic uncertainty about the cause of infections. During the past 8 years, MeMed has collaborated with researchers and clinicians worldwide to study the changes that the immune system undergoes when fighting infections. Building on this research, the company has developed a test that uses human immune signatures to accurately distinguish bacterial and viral infections. ImmunoXpert, the first generation of this test, is already in use in the European Union and has been validated in thousands of patients. MeMed is now developing a second-generation version of the test, which is designed for POC use and provides results in 15 minutes.